Company Brings Together Distinguished Panel of Dental Experts to Advance
the Art, Science and Knowledge of CCLAD in Dentistry
LIVINGSTON, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today reported that earlier this month the Company hosted the First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit in New Orleans. The Summit welcomed a distinguished panel of dental experts who gathered to discuss advancements in the scientific and clinical practice communities toward the common goal of advancing the art, science and knowledge of CCLAD in dentistry.
Joe Martin, Chief Executive Officer of Milestone, noted, "Through this Summit, Milestone hoped to provide a forum for open and objective discussion by a unique blend of academia, key opinion leaders and practicing dentists. The in-depth discussion, debate and exchange of ideas that occurred helped to provide Milestone with confirmation that the STA(TM) System and the CompuDent(R) (formerly known as The WAND(R)) are significant improvements over traditional injection techniques."
The two day Summit was chaired by noted dental anesthetic expert,
Stanley Malamed, DDS, Professor of Anesthesia and Medicine School of
Dentistry at the University of Southern California School of Dentistry. Dr.
Malamed is also a Diplomate of the American Dental Board of Anesthesiology,
as well as a recipient of the Heidebrink Award from the American Dental
Society of Anesthesiology and the Horace Wells Award from the International
Federation of Dental Anesthesia Societies. He has authored more than 100
scientific papers and 16 chapters in various medical and dental journals
and textbooks in the areas of physical evaluation, emergency medicine,
local anesthesia, sedation and general anesthesia. In addition, Dr. Malamed
is the author of three widely used textbooks, published by CV Mosby:
Handbook of Medical Emergencies in the Dental Office (5th edition 2000);
Handbook of Local Anesthesia (4th edition 1997); and Sedation - a guide to
patient management (4th edition 2001).
Summit presenting participants also included:
-- John Brescia, DDS, PC, President of John J. Brescia, DDS, PC, a private
dental practice in River Forest, Illinois;
-- Monika Daublaender, MD, DDS, Associate Professor of Oral Surgery at
Johannes Guttenberg University in Germany;
-- Martin Jablow, DMD, a partner in the firm of Dental Technology
Solutions and general dental practitioner in Woodbridge, New Jersey;
-- William Lieberman, DDS, a nationally recognized pediatric dentist
practicing in Red Bank, New Jersey;
-- Peter Loomer, DDS, PhD, Associate Professor of Clinical Periodontology
at the University of California at San Francisco School of Dentistry;
-- Alfred Reader, DDS, MS, Professor of Advanced Endodontics at Ohio State
University College of Dentistry;
-- Kenneth Reed, DMD, noted dental anesthesiologist and nationally
recognized lecturer on dental anesthesia;
-- John Yagiela, DDS, PhD, Professor of Anesthesiology, Diagnostic and
Surgical Sciences at UCLA School of Dentistry.
This highly productive and interactive forum has yielded a number of exciting ideas on how Milestone can integrate the STA System not only into dental school curricula, but also extend the message to the dental community and patients, alike. Martin stated, "It was perhaps most gratifying to confirm that academics and clinicians, alike, recognize the potentially profound impact that Milestone's CCLAD technology is having on the practice of dentistry."
In February of last year, Milestone introduced to market the STA System, a patented CCLAD system that incorporates the "pressure force feedback" elements of Milestone's patented CompuFlo(R) technology, thereby allowing dentists to administer injections accurately and painlessly into the periodontal ligament space, effectively anesthetizing a single tooth. The STA System is also capable of performing all of the injections that can be done with a conventional dental syringe, including the palatal-anterior superior alveolar, anterior middle superior alveolar and inferior alveolar nerve block. The STA System achieves all of these injections predictably and reliably and additionally allows a new and novel interactive injection technique to be performed called the STA-Intraligamentary injection that identifies the correct location and provides an almost immediate onset of profound anesthesia to a single tooth. Milestone received FDA 510(k) Pre-market Notification acceptance in August 2006 for the marketing and sale of the highly anticipated STA System and has since named Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare products and services to office-based practitioners in the combined North American and European markets, as its exclusive distributor in the United States and Canada.
"In light of the direction and recommendations to the dental community we have derived from this Summit, Milestone looks forward to replicating this event every year," concluded Martin.
About Milestone Scientific Inc.
Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented CompuFlo(TM) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The Single Tooth Anesthesia (STA(TM)) computer-controlled local anesthesia delivery system which uses this technology provides dentists with audible and visual signals as to in-tissue pressure. Milestone's existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company's web site found at http://www.milesci.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the
timing and financial impact of the Milestone's ability to implement its
business plan, expected revenues and future success. These statements
involve a number of risks and uncertainties and are based on assumptions
involving judgments with respect to future economic, competitive and market
conditions and future business decisions, all of which are difficult or
impossible to predict accurately and many of which are beyond Milestone's
control. Some of the important factors that could cause actual results to
differ materially from those indicated by the forward-looking statements
are general economic conditions, failure to achieve expected revenue
growth, changes in our operating expenses, adverse patent rulings, FDA or
legal developments, competitive pressures, changes in customer and market
requirements and standards, and the risk factors detailed from time to time
in Milestone's periodic filings with the Securities and Exchange
Commission, including without limitation, Milestone's Annual Report on Form
10-KSB for the year ended December 31, 2006. The forward looking-statements
in this press release are based upon management's reasonable belief as of
the date hereof. Milestone undertakes no obligation to revise or update
publicly any forward-looking statements for any reason.
FOR MORE INFORMATION, PLEASE CONTACT:
Elite Financial Communications Group, LLC
Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist
407-585-1080 or via email at firstname.lastname@example.org
|SOURCE Milestone Scientific Inc.|
Copyright©2008 PR Newswire.
All rights reserved